GO:0047881 estradiol 17-alpha-dehydrogenase [NAD(P)+] activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047881 describes the reversible NAD(P)+-dependent oxidation of estradiol-17-alpha to estrone, a redox interconversion of estrogenic steroids.
• The activity is attributed to 17beta-estradiol dehydrogenase / 17alpha-hydroxysteroid oxidoreductase enzymes that can use NAD+ or NAD(P)+ as cofactor.
• Human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase activities can reside at a single enzyme active site, illustrating catalytic multifunctionality.
• Steroidogenic regulation of this activity is relevant to teleost reproduction, skeletal muscle steroid metabolism, and porcine intestinal steroid disruption by zearalenone.
• Altered steroid biosynthesis, including 17alpha-hydroxysteroid oxidoreductase steps, is implicated in polycystic ovary syndrome models and endocrine-related pathology.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of GO:0047881-related genes in steroidogenic and metabolic pathways.
Description
GO:0047881, estradiol 17-alpha-dehydrogenase [NAD(P)+] activity, is a molecular function defined by the catalysis of the reaction estradiol-17-alpha + NAD(P)+ = estrone + NAD(P)H + H+. This activity belongs to the oxidoreductase class and interconverts the 17alpha-hydroxy and 17-keto forms of estrogenic steroids using NAD+ or NAD(P)+ as the electron acceptor. Because estrogens are central to reproductive physiology, skeletal muscle biology, and endocrine disruption, enzymes carrying this activity are studied across endocrinology, cancer biology, and toxicology. The activity is often associated with 17beta-estradiol dehydrogenase and 17alpha-hydroxysteroid oxidoreductase enzymes, which have been characterized biochemically in human placenta and other steroidogenic tissues. Researchers use this GO term to annotate gene products that catalyze 17alpha-hydroxysteroid oxidation, enabling comparative analysis of steroidogenic pathways in fish, mammals, and cell models. Understanding GO:0047881 is therefore essential for interpreting estrogen metabolism, designing endocrine experiments, and building CRISPR models that test causal roles of candidate steroidogenic genes.
estradiol 17-alpha-dehydrogenase [NAD(P)+] activity At A Glance
| GO ID | GO:0047881 |
|---|---|
| GO term | estradiol 17-alpha-dehydrogenase [NAD(P)+] activity |
| Ontology | molecular_function |
| Synonym | 17alpha-estradiol dehydrogenase activity; 17alpha-hydroxy steroid dehydrogenase activity; 17alpha-hydroxysteroid:NAD(P)+ 17-oxidoreductase activity; estradiol 17alpha-dehydrogenase activity |
| Major function | Catalysis of estradiol-17-alpha + NAD(P)+ = estrone + NAD(P)H + H+ |
| Reaction direction | Reversible oxidoreduction between 17alpha-hydroxy and 17-keto steroids |
| Cofactor | NAD+ or NAD(P)+ |
| Related activities | 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase activities can co-occur at a single active site |
| Representative tissues | Placenta, gonads, skeletal muscle, intestine, and steroidogenic tissues |
What Is GO:0047881?
In our own words, GO:0047881 describes an enzymatic activity that removes hydride from the 17alpha position of estradiol-17-alpha, converting the 17alpha-hydroxy group to a 17-keto group and producing estrone, while reducing NAD(P)+ to NAD(P)H and releasing a proton. The reaction is reversible and uses NAD+ or NAD(P)+ as the cofactor, placing the activity among NAD(P)+-dependent oxidoreductases that modulate estrogen potency and availability.
Why Is estradiol 17-alpha-dehydrogenase [NAD(P)+] activity Important in Cell Biology?
GO:0047881 is important because it controls the redox balance between estradiol-17-alpha and estrone, thereby influencing estrogenic signaling and steroid hormone homeostasis. This activity is relevant to reproductive biology in teleosts and mammals, to exercise-related sex steroid metabolism in skeletal muscle, and to endocrine disruption by mycotoxins such as zearalenone in the porcine intestinal tract. It also intersects with polycystic ovary syndrome models in which steroid biosynthesis pathway regulation is a therapeutic target. Biochemically, the activity has been used to probe active-site architecture of human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase, revealing that multiple steroid oxidoreductase activities can share a single enzyme active site. For researchers, GO:0047881 provides a precise annotation for genes and enzymes that modulate estrogen potency, making it a key term for endocrine, metabolic, and cancer studies.
• Regulates the interconversion of estradiol-17-alpha and estrone, affecting estrogenic potency.
• Uses NAD+ or NAD(P)+ as cofactor, linking steroid metabolism to cellular redox state.
• Relevant to teleost steroidogenesis and reproductive physiology.
• Implicated in exercise-related sex steroid hormone changes in skeletal muscle.
• Target of endocrine-disrupting compounds such as zearalenone in the porcine intestine.
• Associated with polycystic ovary syndrome steroid biosynthesis pathway dysregulation.
• Provides a biochemical marker for placental steroid oxidoreductase active-site studies.
• Enables annotation of genes with 17alpha-hydroxysteroid oxidoreductase activity in genome databases.
• Supports CRISPR-based causal testing of steroidogenic gene function in cell models.
Molecular Mechanism of estradiol 17-alpha-dehydrogenase [NAD(P)+] activity
Substrate recognition and binding
In simple terms: The enzyme first grabs the steroid substrate and holds it in place.
The enzyme binds estradiol-17-alpha or related 17alpha-hydroxysteroids in a steroid-binding pocket that positions the 17alpha-hydroxy group for catalysis. Affinity labeling studies of human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase have identified active-site residues that interact with steroid substrates and cofactor analogs. The same active site can accommodate different steroid orientations, explaining why 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase activities can coexist in one enzyme.
Cofactor binding and hydride transfer
In simple terms: NAD+ or NAD(P)+ accepts a hydride from the steroid, driving the oxidation.
NAD+ or NAD(P)+ binds in a Rossmann-fold-like cofactor site, and the enzyme transfers a hydride from the 17alpha position of estradiol-17-alpha to the nicotinamide ring, forming NAD(P)H. This step converts the 17alpha-hydroxy group to a 17-keto group, yielding estrone and releasing a proton. The reaction is reversible, so the same enzyme can reduce estrone back to estradiol-17-alpha when NAD(P)H is available.
Active-site chemistry and multifunctionality
In simple terms: One enzyme pocket can perform more than one steroid reaction.
Biochemical studies with 6beta-bromoacetoxyprogesterone and affinity labels have shown that human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase activities share a single active site, indicating that GO:0047881-related chemistry can be catalyzed by enzymes with broad steroid oxidoreductase specificity. The absence of zinc does not abolish full enzymatic activity of estradiol 17beta-dehydrogenase, distinguishing it from zinc-dependent dehydrogenases.
Regulation by steroidogenic pathways
In simple terms: Hormones and metabolic signals can change how much of this enzyme activity is present.
Steroidogenesis is regulated by trophic hormones and developmental cues in teleosts, and 17alpha-hydroxysteroid oxidoreductase steps are embedded in these pathways. Exercise and sex steroid hormones in skeletal muscle also modulate steroid metabolic enzymes, including 17beta-estradiol dehydrogenase activity. In polycystic ovary syndrome models, regulation of the steroid biosynthesis pathway affects estrogen and androgen balance, implicating GO:0047881-related steps.
Endocrine disruption and substrate competition
In simple terms: Foreign compounds can interfere with the enzyme and alter steroid levels.
Zearalenone activity in the porcine intestinal tract affects steroid metabolism, and such endocrine-disrupting compounds can compete with or modulate 17alpha-hydroxysteroid oxidoreductase reactions. Because the reaction is reversible and cofactor-dependent, changes in NAD(P)+/NAD(P)H ratio can shift the equilibrium between estradiol-17-alpha and estrone.
Key Genes Involved in GO:0047881 estradiol 17-alpha-dehydrogenase [NAD(P)+] activity
The following genes and proteins are experimentally linked to estradiol 17-alpha-dehydrogenase [NAD(P)+] activity or its related steroid oxidoreductase functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HSD17B1 | 17beta-estradiol dehydrogenase / 17alpha-hydroxysteroid oxidoreductase | Human placental enzyme with affinity-labeling and active-site studies |
| HSD17B2 | 17beta-hydroxysteroid dehydrogenase type 2 | Estrogen inactivation via 17-keto formation |
| HSD17B3 | 17beta-hydroxysteroid dehydrogenase type 3 | Testicular androgen synthesis and steroidogenesis |
| HSD17B4 | Peroxisomal 17beta-hydroxysteroid dehydrogenase type 4 | Steroid and fatty acid metabolism |
| HSD17B5 | 17beta-hydroxysteroid dehydrogenase type 5 | Androgen and estrogen interconversion |
| HSD17B6 | 17beta-hydroxysteroid dehydrogenase type 6 | Retinoid and steroid oxidoreduction |
| HSD17B7 | 17beta-hydroxysteroid dehydrogenase type 7 | Cholesterol and steroid biosynthesis |
| HSD17B8 | 17beta-hydroxysteroid dehydrogenase type 8 | Steroidogenic enzyme in reproductive tissues |
| HSD17B10 | 17beta-hydroxysteroid dehydrogenase type 10 | Mitochondrial steroid and neurosteroid metabolism |
| HSD17B11 | 17beta-hydroxysteroid dehydrogenase type 11 | Lipid and steroid metabolism |
| HSD17B12 | 17beta-hydroxysteroid dehydrogenase type 12 | Fatty acid and estrogen metabolism |
| HSD17B13 | 17beta-hydroxysteroid dehydrogenase type 13 | Liver steroid and lipid metabolism |
| HSD17B14 | 17beta-hydroxysteroid dehydrogenase type 14 | Retinal and steroid oxidoreduction |
| CYP19A1 | Aromatase | Estrogen biosynthesis upstream of 17alpha-hydroxysteroid oxidoreductase |
| STS | Steroid sulfatase | Estrogen precursor activation |
| SRD5A1 | 5alpha-reductase type 1 | Androgen metabolism intersecting with estrogen pathways |
| SRD5A2 | 5alpha-reductase type 2 | Androgen metabolism intersecting with estrogen pathways |
How Is estradiol 17-alpha-dehydrogenase [NAD(P)+] activity Regulated?
Regulation of GO:0047881-related activity occurs at multiple levels. Steroidogenic enzyme expression is controlled by trophic hormones and developmental signals in teleosts, where 17alpha-hydroxysteroid oxidoreductase steps are embedded in the steroidogenic cascade. In skeletal muscle, exercise modulates sex steroid hormones and their metabolizing enzymes, including 17beta-estradiol dehydrogenase activity. Endocrine-disrupting compounds such as zearalenone can alter intestinal steroid metabolism, indirectly affecting 17alpha-hydroxysteroid oxidoreductase reactions. In polycystic ovary syndrome models, regulation of the steroid biosynthesis pathway changes the balance of estrogenic and androgenic steroids, implicating GO:0047881-related steps. At the enzyme level, cofactor availability (NAD(P)+/NAD(P)H ratio) and substrate competition determine the direction and rate of the reversible reaction.
estradiol 17-alpha-dehydrogenase [NAD(P)+] activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSD17B1 | Estrogen-dependent cancers and placental steroidogenesis | Knockout and point-mutation cell lines |
| CYP19A1 | Polycystic ovary syndrome and estrogen excess | Knock-in reporter and overexpression models |
| HSD17B2 | Endometriosis and estrogen inactivation defects | CRISPR knockout in endometrial cells |
| HSD17B3 | Disorders of sex development | Point-mutation knock-in in steroidogenic cells |
| HSD17B10 | Neurosteroid-related neurodegeneration | Overexpression and knockout neuronal models |
Polycystic ovary syndrome and steroid biosynthesis dysregulation
Polycystic ovary syndrome is associated with altered steroid biosynthesis, and therapeutic interventions such as Erchen Decoction ameliorate rat models by regulating the steroid biosynthesis pathway. Because GO:0047881 controls the interconversion of estradiol-17-alpha and estrone, changes in this activity could contribute to the estrogen-androgen imbalance seen in PCOS. Researchers use PCOS models to test whether modulating 17alpha-hydroxysteroid oxidoreductase activity restores steroid homeostasis.
Endocrine disruption by zearalenone
Zearalenone, a mycotoxin with estrogenic activity, affects the porcine intestinal tract and steroid metabolism. Its activity can interfere with 17alpha-hydroxysteroid oxidoreductase reactions, potentially altering estrogenic signaling in exposed animals. This makes GO:0047881 a relevant annotation for toxicological studies of endocrine-disrupting compounds.
Reproductive and skeletal muscle steroid metabolism
In teleosts, steroidogenesis and its regulation are essential for reproduction, and 17alpha-hydroxysteroid oxidoreductase steps participate in estrogen synthesis. In skeletal muscle, exercise alters sex steroid hormones and their metabolizing enzymes, including 17beta-estradiol dehydrogenase activity, linking GO:0047881 to exercise physiology. Dysregulation of these pathways may contribute to reproductive and metabolic disorders.
Placental steroid oxidoreductase and cancer biology
Human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase have been studied as models of steroid oxidoreductase active-site chemistry, with implications for understanding hormone-dependent cancers. Affinity labeling and active-site probes have revealed that a single enzyme can catalyze multiple steroid reactions, which is relevant to designing inhibitors for estrogen-dependent diseases.
From estradiol 17-alpha-dehydrogenase [NAD(P)+] activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HSD17B1 alter estradiol-17-alpha to estrone conversion? | CRISPR knockout cell line |
| Does a specific active-site residue control 17alpha-hydroxysteroid oxidoreductase activity? | Point-mutation knock-in |
| Can a tagged enzyme be used to track subcellular localization? | Tagged knock-in |
| Does overexpression of HSD17B2 reduce estrogenic signaling? | Overexpression cell model |
| Which genes in the steroid biosynthesis pathway are regulated in PCOS? | CRISPR library screening and RNA-seq |
| Can endocrine-disrupting compounds inhibit GO:0047881 activity? | Reporter and biochemical assays in intestinal cells |
How to Study the estradiol 17-alpha-dehydrogenase [NAD(P)+] activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NAD(P)H absorbance assay | Enzyme activity via cofactor reduction | Kinetic characterization of GO:0047881 |
| Affinity labeling | Active-site residue interactions | Mapping steroid oxidoreductase active site |
| LC-MS/MS steroid profiling | Estradiol-17-alpha and estrone levels | Endocrine disruption and PCOS studies |
| RNA-seq | Transcriptomic changes in steroidogenic genes | Pathway analysis in disease models |
| CRISPR knockout screening | Gene requirement for enzyme activity | Functional genomics of steroid metabolism |
| Western blot | Protein expression of HSD17B enzymes | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization of tagged enzyme | Organelle-specific steroid metabolism |
| Reporter gene assay | Transcriptional response to steroids | Endocrine-disrupting compound testing |
Biochemical enzyme assays
Direct measurement of estradiol 17-alpha-dehydrogenase [NAD(P)+] activity uses NAD(P)+ reduction to NAD(P)H monitored spectrophotometrically at 340 nm, with estradiol-17-alpha as substrate. Affinity labeling with 5'-[p-(fluorosulfonyl)benzoyl]adenosine and 6beta-bromoacetoxyprogesterone has been used to probe active-site residues of human placental 17beta-estradiol dehydrogenase. These assays provide kinetic constants and cofactor preferences for GO:0047881-related enzymes.
Steroid profiling by mass spectrometry
LC-MS/MS or GC-MS steroid profiling quantifies estradiol-17-alpha, estrone, and related steroids in cells or tissues, allowing inference of 17alpha-hydroxysteroid oxidoreductase flux. This approach is used in PCOS models and teleost steroidogenesis studies to link enzyme activity to hormone output.
Transcriptomics and pathway analysis
RNA-seq and pathway enrichment identify steroid biosynthesis genes whose expression changes with disease or treatment, as shown in PCOS rat models treated with Erchen Decoction. These datasets help prioritize candidate genes for CRISPR knockout or overexpression studies of GO:0047881-related activity.
CRISPR screening and functional genomics
Pooled CRISPR knockout libraries coupled with steroid readouts can systematically identify genes required for estradiol-17-alpha to estrone conversion. Bioinformatics analysis of screening hits maps candidates to steroidogenic pathways and GO terms including GO:0047881.
How CRISPR Can Be Used to Study GO:0047881 estradiol 17-alpha-dehydrogenase [NAD(P)+] activity
Knockout
CRISPR knockout of HSD17B1 or related genes eliminates estradiol 17-alpha-dehydrogenase [NAD(P)+] activity, allowing researchers to measure the contribution of a single enzyme to estrone production. Knockout cell lines can be profiled by steroid mass spectrometry and RNA-seq to reveal compensatory pathways.
Point Mutation
Point mutations in active-site residues identified by affinity labeling can be introduced to test their role in hydride transfer and substrate binding. Such models distinguish catalytic residues from structural ones and validate biochemical mechanisms of GO:0047881.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous locus enables tracking of enzyme localization and interaction partners without overexpression artifacts. Tagged knock-in models are useful for imaging steroidogenic enzyme dynamics in live cells.
Overexpression
Overexpression of HSD17B enzymes increases 17alpha-hydroxysteroid oxidoreductase flux, providing a gain-of-function system to test effects on estrogen signaling and cell proliferation. Overexpression models complement knockout studies to establish causality in steroid-dependent phenotypes.
How EDITGENE Supports estradiol 17-alpha-dehydrogenase [NAD(P)+] activity Research
Researchers studying estradiol 17-alpha-dehydrogenase [NAD(P)+] activity-related genes often need to determine whether a candidate gene is causally involved in estrogen metabolism or simply correlated with a phenotype. EDITGENE provides publication-ready CRISPR cell models and screening services that enable precise, reproducible interrogation of GO:0047881-related biology.
Contact EDITGENE today to design your custom CRISPR model for estradiol 17-alpha-dehydrogenase [NAD(P)+] activity research.
Frequently Asked Questions About estradiol 17-alpha-dehydrogenase [NAD(P)+] activity
What is estradiol 17-alpha-dehydrogenase [NAD(P)+] activity?
It is the enzymatic activity defined by GO:0047881 that catalyzes estradiol-17-alpha + NAD(P)+ = estrone + NAD(P)H + H+, interconverting 17alpha-hydroxy and 17-keto estrogens.
What genes are involved in estradiol 17-alpha-dehydrogenase [NAD(P)+] activity?
Genes such as HSD17B1, HSD17B2, and other HSD17B family members encode enzymes with 17alpha-hydroxysteroid oxidoreductase activity.
What is the reaction catalyzed by GO:0047881?
The reaction is estradiol-17-alpha + NAD(P)+ = estrone + NAD(P)H + H+, a reversible oxidoreduction.
Which cofactors are used by estradiol 17-alpha-dehydrogenase?
The enzyme uses NAD+ or NAD(P)+ as the electron acceptor, producing NAD(P)H.
Is estradiol 17-alpha-dehydrogenase activity related to polycystic ovary syndrome?
Yes, steroid biosynthesis pathway dysregulation is implicated in PCOS models, and GO:0047881-related steps may contribute to estrogen-androgen imbalance.
How is estradiol 17-alpha-dehydrogenase activity measured?
It is measured by NAD(P)H absorbance assays, steroid mass spectrometry, and affinity labeling of active-site residues.
Can CRISPR knockout be used to study GO:0047881?
Yes, CRISPR knockout of HSD17B genes eliminates the activity and allows functional studies of estrogen metabolism.
What diseases are linked to estradiol 17-alpha-dehydrogenase activity?
PCOS, endocrine disruption by zearalenone, and estrogen-dependent cancers are linked to this activity.
What is the difference between 17alpha and 17beta estradiol dehydrogenase?
Both are steroid oxidoreductases, but they act on different stereochemical positions; human placental 17beta-estradiol dehydrogenase can also display 20alpha-hydroxysteroid dehydrogenase activity at a single active site.
How does exercise affect estradiol 17-alpha-dehydrogenase activity?
Exercise modulates sex steroid hormones and metabolizing enzymes in skeletal muscle, including 17beta-estradiol dehydrogenase activity.
Conclusion
GO:0047881, estradiol 17-alpha-dehydrogenase [NAD(P)+] activity, is a well-defined molecular function that controls the reversible redox interconversion of estradiol-17-alpha and estrone using NAD(P)+ as cofactor. Its relevance spans teleost steroidogenesis, skeletal muscle exercise physiology, endocrine disruption, PCOS, and placental steroid oxidoreductase biochemistry. By combining biochemical assays, steroid profiling, and CRISPR models, researchers can causally test the role of HSD17B family genes and other candidates in estrogen metabolism. EDITGENE provides the knockout, point-mutation, knock-in, overexpression, and screening platforms needed to accelerate this research.
References
- 1. Rajakumar A et al.. 2020. Steroidogenesis and its regulation in teleost-a review.. Fish Physiol Biochem 46(3):803-818 PMID: 31940121
- 2. Sato K et al.. 2015. Exercise and sex steroid hormones in skeletal muscle.. J Steroid Biochem Mol Biol 145:200-5 PMID: 24704257
- 3. Gajęcka M et al.. 2016. Activity of Zearalenone in the Porcine Intestinal Tract.. Molecules 22(1) PMID: 28029134
- 4. Murdock GL et al.. 1991. Estradiol 17 beta-dehydrogenase: full enzymatic activity in the absence of zinc.. Biochim Biophys Acta 1076(2):197-202 PMID: 1998720
- 5. Zhang J et al.. 2025. Erchen Decoction ameliorates the rat model of polycystic ovary syndrome by regulating the steroid biosynthesis pathway.. Phytomedicine 143:156852 PMID: 40446578
- 6. Tobias B et al.. 1981. Affinity labeling of human placental 17 beta-estradiol dehydrogenase and 20 alpha-hydroxysteroid dehydrogenase with 5'-[p-(fluorosulfonyl)benzoyl]adenosine.. Biochemistry 20(19):5546-9 PMID: 6945875
- 7. Thomas JL et al.. 1983. Human placental 17 beta-estradiol dehydrogenase and 20 alpha-hydroxysteroid dehydrogenase. Studies with 6 beta-bromoacetoxyprogesterone.. J Biol Chem 258(3):1587-90 PMID: 6571837
- 8. Strickler RC et al.. 1981. Human placental 17 beta-estradiol dehydrogenase and 20 alpha-hydroxysteroid dehydrogenase. Two activities at a single enzyme active site.. J Biol Chem 256(1):316-21 PMID: 6935192
